BioCentury
ARTICLE | Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

August 4, 2020 12:36 AM UTC

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development.

TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front and $4 million on Dec. 30 to cover R&D expenses, and Dynavax is eligible for up to $250 million in milestones, plus low double-digit royalties. ...

BCIQ Company Profiles

Dynavax Technologies Corp.

BCIQ Target Profiles

Toll-like receptor 9 (TLR9)